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Given several high-profile recalls in recent
years of pharmaceuticals by the US Food and
Drug Administration (FDA), the subject of
pharmaceutical risk management has become
increasingly important. Pharmaceutical risk
management refers to manufacturers creating
special tools and programs to ensure the safe
use of certain high risk products. The FDA’s
Amendments Act (FDAAA) of 2007 prompted the
Food and Drug Law Institute (FDLI) to publish
Pharmaceutical Risk Management: Practical
Applications (2008), a follow up to their 2003
publication, A Framework for Pharmaceutical Risk
Management. The 2008 edition is a multi-author
work written by experienced risk managers who
have organized risk management programs as
consultants or industry executives; some are
alumni of the FDA. It is important to note that
this is not a second edition of the 2003 book,
but rather an extension of the research and
methods presented in the original, with an
emphasis on practical applications of risk
management principles. The purpose of this
publication is to educate pharmaceutical
companies, consultants, and other drug industry
stakeholders on the new rules for Risk Evaluation
and Mitigation strategies (REMS) during preand post-marketing drug development.
Pharmaceutical Risk Management: Practical
Applications provides the historical context for all

of the recent changes in the FDA’s requirements
for risk management, which culminated with
the FDAAA of 2007. The authors describe the
Vioxx® withdrawal from the market and how it
ultimately compelled the Institute of Medicine
(IOM) to issue its report, The Future of Drug
Safety: Promoting and Protecting the Health of
the Public, which pointed out deficiencies in drug
safety in the US and made recommendations for
correcting them. Some of these recommendations
were incorporated in the FDAAA of 2007, including
the expanded ability of the FDA to require a
REMS if the agency deems the strategy would be
“necessary to ensure that the benefits of the drug
outweigh the risks of the drug.” The legislation also
allows the FDA to require a REMS for a previously
approved drug if it “becomes aware of new safety
information and makes a determination that such
a strategy is necessary to ensure that the benefits
of the drug outweigh its risks.”
The author/s goes on to address specific elements
of a REMS or risk management action plan
(RiskMAP). It details the application of risk
management to clinical development, regulator
approval, clinician acceptance, and outcomes
improvement. Incorporating educational
interventions into risk management is explored,
as is evaluating the performance of risk
management plans. The authors conclude with
chapters on crisis avoidance and management,

and the legal implications of risk management.
An extensive appendix is also provided, including
three guidance documents on risk management
published by the FDA in 2005, the FDAAA of
2007, a list of products with approved REMS in
effect when the FDAAA was passed, and a March
2008 draft of the Prescription Drug User Fee Act
(PDUFA) IV: Drug Safety Five-Year Plan.
This FDLI publication on pharmaceutical risk
management, when accompanied by A Framework
for Pharmaceutical Risk Management (2003), acts
as an excellent primer for individuals devising
or interpreting a REMS or RiskMAP for the
FDA, and could also be helpful for devising risk
management strategies internally or for other
regulatory agencies. The book provides firsthand knowledge from a collection of authors
who have extensive training and experience in
the field of pharmaceutical risk management.
Both manufacturers and the FDA hope that
effective risk management programs will protect
consumers from future recalls and increase the
safety of medications in the US. 
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